Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple types of refractory seizures. Despite the availability of approved therapies such as Diacomit, Epidiolex, and Fintepla, most patients continue to experience uncontrolled seizures and substantial comorbidities, highlighting the persistent unmet need for treatments that can meaningfully modify disease progression. This report examines the key factors shaping prescribers’ clinical decisionmaking and their perceptions of existing therapies, offering actionable insights to help drug developers optimally position and differentiate new products for this rare and challenging form of epilepsy.
Questions answered
- What are the key treatment goals and clinical priorities in managing Dravet syndrome?
- Which treatment attributes most strongly influence neurologists’ decisionmaking, which have minimal impact, and where do hidden opportunities for differentiation exist?
- How do current therapies (e.g., Diacomit, Epidiolex, Fintepla) perform across critical clinical and nonclinical attributes?
- What are the leading unmet needs and areas of opportunity within the current treatment landscape?
- Based on a conjoint analysis and TPP simulation, what tradeoffs across clinical attributes and pricing are neurologists willing to accept for a hypothetical Dravet syndrome (DS) therapy?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in March 2026
Key drugs: Diacomit, Epidiolex, Fintepla, clobazam, and levetiracetam
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key analyses
- Importance of clinical and nonclinical product attributes to physicians
- Assessment of current drug performance against treatment drivers and goals
- Physician perceptions of unmet needs in the indication and related indications
- Remaining drug development opportunities
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
